Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionerythropoietin receptor binding

RNF41 LYN

1.60e-0441042GO:0005128
GeneOntologyMolecularFunctionguanyl-nucleotide exchange factor activity

MYCBP2 BCR DIS3 ITSN2 ARHGEF9 THG1L FGD5

2.08e-042311047GO:0005085
HumanPhenoShort ribs

EVC2 KIAA0586 LAMA5 RTL1 DHCR24 FGFR3

1.99e-0574406HP:0000773
HumanPhenoHypoplastic ribs

EVC2 KIAA0586 LAMA5 RTL1 DHCR24 FGFR3

1.99e-0574406HP:0000908
Domain-

RBM15 XRCC6

3.10e-04510522.40.290.10
DomainSPOC-like_C_dom

RBM15 XRCC6

3.10e-0451052IPR016194
DomainRhoGEF

BCR ITSN2 ARHGEF9 FGD5

5.83e-04681054SM00325
DomainRhoGEF

BCR ITSN2 ARHGEF9 FGD5

6.50e-04701054PF00621
DomainDH_2

BCR ITSN2 ARHGEF9 FGD5

6.50e-04701054PS50010
Domain-

BCR ITSN2 ARHGEF9 FGD5

6.86e-047110541.20.900.10
DomainDH-domain

BCR ITSN2 ARHGEF9 FGD5

6.86e-04711054IPR000219
DomainSer-Thr/Tyr_kinase_cat_dom

CSK NEK5 FGFR3 LYN EPHA3

1.09e-031381055IPR001245
DomainTyr_kinase_cat_dom

CSK FGFR3 LYN EPHA3

1.53e-03881054IPR020635
DomainTyrKc

CSK FGFR3 LYN EPHA3

1.53e-03881054SM00219
DomainRRM_dom

RBM15 RBMXL3 RBM33 MSI1 MSI2 SYNJ2

1.79e-032271056IPR000504
DomainRRM

RBM15 RBMXL3 RBM33 MSI1 MSI2 SYNJ2

1.91e-032301056PS50102
DomainPROTEIN_KINASE_TYR

CSK FGFR3 LYN EPHA3

2.19e-03971054PS00109
DomainTyr_kinase_AS

CSK FGFR3 LYN EPHA3

2.19e-03971054IPR008266
Domain-

RBM15 RBMXL3 RBM33 MSI1 MSI2 SYNJ2

2.56e-0324410563.30.70.330
DomainNucleotide-bd_a/b_plait

RBM15 RBMXL3 RBM33 MSI1 MSI2 SYNJ2

3.38e-032581056IPR012677
DomainCyclin_C-dom

CCND1 CCNB1

4.03e-03171052IPR004367
DomainCyclin_C

CCND1 CCNB1

4.03e-03171052PF02984
DomainCytidine_deaminase-like

CDADC1 ATIC

4.03e-03171052IPR016193
DomainCyclin_C

CCND1 CCNB1

4.03e-03171052SM01332
DomainProtein_kinase_ATP_BS

CSK NEK5 PRKCQ FGFR3 LYN EPHA3 MAP3K19

5.57e-033791057IPR017441
PathwayWP_TRANSSULFURATION_PATHWAY

CBS CSAD MTR

2.05e-0510803M39324
PathwayWP_METHIONINE_METABOLISM_LEADING_TO_SULFUR_AMINO_ACIDS_AND_RELATED_DISORDERS

CBS CSAD MTR

2.81e-0511803M39741
PathwayWP_CYSTEINE_AND_METHIONINE_CATABOLISM

CBS CSAD MTR

7.62e-0515803M39790
Pubmed

Systems analysis of RhoGEF and RhoGAP regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions.

TPR RBM15 AHCYL1 ARHGAP36 RBM33 NOC2L MSI1 HUWE1 BCR CBS MFAP1 ITSN2 ARHGEF9 PYCR1 FGD5

1.27e-079161061532203420
Pubmed

Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.

TPR RBM15 NOC2L NSD2 KIAA0586 HUWE1 CBS DIS3 SLC38A2 DHCR24 MTR PYCR1 TLN2 FGD5 ATIC BSN STAG2 XRCC6

3.00e-0714251061830948266
Pubmed

An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.

ELOA MYCBP2 RBM33 HUWE1 BCR SLC38A2 MFAP1 TBC1D31 SYNJ2 MTR TYW1 ATIC VCPIP1

3.84e-077331061334672954
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

NSD2 CECR2 LAMA5 BCR DIS3 GGA3 SLC38A2 MTUS1 SYNJ2 DHCR24 BSN

6.88e-075291061114621295
Pubmed

Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.

TPR RBM15 MYCBP2 NOC2L NSD2 BEND3 HUWE1 DIS3 ATIC STAG2 XRCC6 PRRC2B

7.66e-076531061222586326
Pubmed

A Large-scale genetic association study of esophageal adenocarcinoma risk.

COL12A1 CYP24A1 CCND1 CBS CCNB1 CSK MTR MMP3 XRCC6

1.36e-06351106920453000
Pubmed

CLEC16A interacts with retromer and TRIM27, and its loss impairs endosomal trafficking and neurodevelopment.

MYCBP2 MSI1 HUWE1 BCR CBS DIS3 DHCR24 MTR PYCR1 RNF41 XRCC6

2.56e-066061061136538041
Pubmed

Inhibition of RIF1 by SCAI Allows BRCA1-Mediated Repair.

BCR AHDC1 BSN

5.93e-0612106328700933
Pubmed

Quantitative trait loci affecting the 3D skull shape and size in mouse and prioritization of candidate genes in-silico.

ASXL1 NSD2 FGFR3 EPHA3

6.18e-0639106425859222
Pubmed

In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.

ELOA AHCYL1 NOC2L NSD2 ANKRD30B BEND3 MFAP1 TBC1D31 ITSN2 PYCR1 BSN LRMDA DNAH8 STAG2 XRCC6 PRRC2B

7.67e-0614421061635575683
Pubmed

Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia.

NSD2 CBS F13A1 DHCR24 MTR FGF12 FGFR3 ATIC

8.31e-06331106820634891
Pubmed

Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer.

MSI1 MSI2

9.20e-062106232245259
Pubmed

Type XII collagen contributes to diversities in human corneal and limbal extracellular matrices.

COL12A1 C3

9.20e-06210629344363
Pubmed

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

NSD2 FGFR3

9.20e-06210629207791
Pubmed

The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity.

MSI1 MSI2

9.20e-062106216717192
Pubmed

Theoretical studies on RNA recognition by Musashi 1 RNA-binding protein.

MSI1 MSI2

9.20e-062106235840700
Pubmed

Dysregulated Stem Cell Markers Musashi-1 and Musashi-2 are Associated with Therapy Resistance in Inflammatory Breast Cancer.

MSI1 MSI2

9.20e-062106237481823
Pubmed

Assessment of MUSASHI 1 and MUSASHI 2 expression in spermatozoa and testicular tissue.

MSI1 MSI2

9.20e-062106234309875
Pubmed

Estrogen and progesterone lower cyclin B1 AND D1 expression, block cell cycle in G2/M, and trigger apoptosis in human adrenal carcinoma cell cultures.

CCND1 CCNB1

9.20e-062106218491248
Pubmed

Interplay between the RNA binding-protein Musashi and developmental signaling pathways.

MSI1 MSI2

9.20e-062106231692135
Pubmed

Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells.

MSI1 MSI2

9.20e-062106234768932
Pubmed

Protein kinase C theta is expressed in mast cells and is functionally involved in Fcepsilon receptor I signaling.

PRKCQ LYN

9.20e-062106211358993
Pubmed

A dominant function of LynB kinase in preventing autoimmunity.

CSK LYN

9.20e-062106235452291
Pubmed

Crystal and solution structures of human oncoprotein Musashi-2 N-terminal RNA recognition motif 1.

MSI1 MSI2

9.20e-062106231603583
Pubmed

Polymorphisms in methionine synthase (A2756G) and cystathionine beta-synthase (844ins68) and susceptibility to carcinomas of the upper gastrointestinal tract.

CBS MTR

9.20e-062106217726616
Pubmed

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.

NSD2 FGFR3

9.20e-062106218036184
Pubmed

Expression of RNA-binding protein Musashi in hair follicle development and hair cycle progression.

MSI1 MSI2

9.20e-062106216400011
Pubmed

PGC-1α regulates the cell cycle through ATP and ROS in CH1 cells.

CCND1 CCNB1

9.20e-062106226834014
Pubmed

ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.

ASXL1 STAG2

9.20e-062106234529785
Pubmed

Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.

CCND1 FGFR3

9.20e-062106219070887
Pubmed

A primate-specific RNA-binding protein (RBMXL3) is involved in glucocorticoid regulation of human pulmonary surfactant protein B (SP-B) mRNA stability.

RBMXL3 SFTPB

9.20e-062106233719563
Pubmed

The Musashi proteins MSI1 and MSI2 are required for photoreceptor morphogenesis and vision in mice.

MSI1 MSI2

9.20e-062106233168629
Pubmed

Msi RNA-binding proteins control reserve intestinal stem cell quiescence.

MSI1 MSI2

9.20e-062106227799368
Pubmed

Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state.

MSI1 MSI2

9.20e-062106225380226
Pubmed

Musashi expression in β-cells coordinates insulin expression, apoptosis and proliferation in response to endoplasmic reticulum stress in diabetes.

MSI1 MSI2

9.20e-062106222113197
Pubmed

Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.

MSI1 MSI2

9.20e-062106228143872
Pubmed

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.

NSD2 FGFR3

9.20e-062106212433679
Pubmed

Knockout of RNA Binding Protein MSI2 Impairs Follicle Development in the Mouse Ovary: Characterization of MSI1 and MSI2 during Folliculogenesis.

MSI1 MSI2

9.20e-062106226131972
Pubmed

RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation.

MSI1 MSI2

9.20e-062106212407178
Pubmed

RNA binding proteins in spermatogenesis: an in depth focus on the Musashi family.

MSI1 MSI2

9.20e-062106225851660
Pubmed

LncRNA FGD5-AS1 Promotes Abdominal Aortic Aneurysm Growth Through the Activation of MMP3 in Vascular Smooth Muscle Cells.

FGD5 MMP3

9.20e-062106237197924
Pubmed

Expression profiling of cyclin B1 and D1 in cervical carcinoma.

CCND1 CCNB1

9.20e-062106216614707
Pubmed

Immunohistochemical Analysis Revealed a Correlation between Musashi-2 and Cyclin-D1 Expression in Patients with Oral Squamous Cells Carcinoma.

CCND1 MSI2

9.20e-062106231878037
Pubmed

Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins.

MSI1 MSI2

9.20e-062106230097032
Pubmed

Systematic analysis of human protein complexes identifies chromosome segregation proteins.

TPR ASXL1 CCNB1 CSK SYNJ2 ITSN2 COPS7B TLN2 RNF41 MORC3 STAG2 XRCC6 PRRC2B ALPG

1.13e-0511551061420360068
Pubmed

The human cytoplasmic dynein interactome reveals novel activators of motility.

GPBP1 NOC2L BCR GGA3 TBC1D31 MTUS1 SYNJ2 ITSN2 MORC3 LYN PRRC2B VCPIP1

1.17e-058531061228718761
Pubmed

A High-Density Human Mitochondrial Proximity Interaction Network.

MYCBP2 RBM33 BEND3 MSI1 HUWE1 MFN1 CCNB1 MSI2 ITSN2 THG1L MTR PYCR1 PRKCQ XRCC6 PRRC2B VCPIP1

1.21e-0514961061632877691
Pubmed

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.

RBM15 RBM33 HUWE1 BCR DIS3 MTR MORC3 BSN PRRC2B VCPIP1

1.32e-055881061038580884
Pubmed

TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.

SLC38A2 KLHL3 FDFT1 ITSN2 NFYB PYCR1 FGD5 BSN STAG2 PRRC2B

2.64e-056381061031182584
Pubmed

Differential mitotic activation of endogenous c-Src, c-Yes, and Lyn in HeLa cells.

CSK LYN

2.76e-053106217692281
Pubmed

[Effect of polymorphisms on key enzymes in homocysteine metabolism, on plasma homocysteine level and on coronary artery-disease risk in a Tunisian population].

CBS MTR

2.76e-053106218620331
Pubmed

Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer's disease.

MSI1 MSI2

2.76e-053106230367664
Pubmed

The Musashi proteins direct post-transcriptional control of protein expression and alternate exon splicing in vertebrate photoreceptors.

MSI1 MSI2

2.76e-053106236153373
Pubmed

Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis.

GGA3 DHCR24

2.76e-053106219815556
Pubmed

Polymorphisms in MTHFR, MS and CBS genes and homocysteine levels in a Pakistani population.

CBS MTR

2.76e-053106222470444
Pubmed

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

ASXL1 STAG2

2.76e-053106230004110
Pubmed

Mitofusin 1 is degraded at G2/M phase through ubiquitylation by MARCH5.

MFN1 CCNB1

2.76e-053106223253261
Pubmed

Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells.

TLN2 PRKCQ

2.76e-053106218792400
Pubmed

Gene-environment and gene-gene interactions of specific MTHFR, MTR and CBS gene variants in relation to homocysteine in black South Africans.

CBS MTR

2.76e-053106223954866
Pubmed

[Correlation analysis between plasma homocysteine level and polymorphism of homocysteine metabolism related enzymes in ischemic cerebrovascular or cardiovascular diseases].

CBS MTR

2.76e-053106212015064
Pubmed

Tau oligomers mediate aggregation of RNA-binding proteins Musashi1 and Musashi2 inducing Lamin alteration.

MSI1 MSI2

2.76e-053106231532069
Pubmed

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.

CCND1 CCNB1

2.76e-053106219470724
Pubmed

Depletion of Csk preferentially reduces the protein level of LynA in a Cbl-dependent manner in cancer cells.

CSK LYN

2.76e-053106232376886
Pubmed

[Study on the association of polymorphisms in homocysteine metabolism related enzymes with deep venous thrombosis].

CBS MTR

2.76e-053106217160942
Pubmed

STAP-2 negatively regulates BCR-mediated B cell activation by recruiting tyrosine-protein kinase CSK to LYN.

CSK LYN

2.76e-053106237669828
Pubmed

Effects of nickel on cyclin expression, cell cycle progression and cell proliferation in human pulmonary cells.

CCND1 CCNB1

2.76e-053106219505905
Pubmed

CD19 signaling is impaired in murine peritoneal and splenic B-1 B lymphocytes.

BCR LYN

2.76e-053106219541367
Pubmed

A human short open reading frame (sORF)-encoded polypeptide that stimulates DNA end joining.

CYREN XRCC6

2.76e-053106224610814
Pubmed

Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men.

CBS MTR

2.76e-053106211204591
Pubmed

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.

NSD2 CCND1

2.76e-053106231218784
Pubmed

Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast.

CCND1 CCNB1

2.76e-053106225501285
Pubmed

RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction.

MSI1 MSI2

2.76e-053106232855391
Pubmed

Polymorphisms in the folate-metabolizing genes MTR, MTRR, and CBS and breast cancer risk.

CBS MTR

2.76e-053106222236648
Pubmed

A comparative study of the phosphotyrosyl phosphatase specificity of protein phosphatase type 2A and phosphotyrosyl phosphatase type 1B using phosphopeptides and the phosphoproteins p50/HS1, c-Fgr and Lyn.

CSK LYN

2.76e-05310628612628
Pubmed

Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma.

CBS MTR

2.76e-053106211074524
Pubmed

Polymorphisms in genes involved in folate metabolism as risk factors for oedematous severe childhood malnutrition: a hypothesis-generating study.

CBS MTR

2.76e-053106216709328
Pubmed

Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases.

CBS MTR

2.76e-053106211672761
Pubmed

Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN.

CYREN XRCC6

2.76e-053106228959974
Pubmed

Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.

CBS MTR

2.76e-053106212154064
Pubmed

IHG-1 increases mitochondrial fusion and bioenergetic function.

MFN1 THG1L

2.76e-053106225008184
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

ASXL1 BEND3 GGA3 EPG5 ITSN2 ARHGEF9 PRRC2B VCPIP1

3.65e-05407106812693553
Pubmed

Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in the liver.

CBS MTR ATIC

5.32e-0524106317937387
Pubmed

Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts.

CSK LYN

5.50e-054106218070987
Pubmed

Relationship between polymorphisms in genes involved in homocysteine metabolism and maternal risk for Down syndrome in Brazil.

CBS MTR

5.50e-054106215889417
Pubmed

Novel Role of the ALPI Gene Associated with Constipation Caused by Complement Component 3 Deficiency.

C3 ALPG

5.50e-054106239273477
Pubmed

5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review.

CBS MTR

5.50e-054106210791559
Pubmed

[Study of serum Hcy and polymorphisms of Hcy metabolic enzymes in 192 families affected by congenital heart disease].

CBS MTR

5.50e-054106215719048
Pubmed

PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia.

CSK LYN

5.50e-054106221513978
Pubmed

Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults.

CBS MTR

5.50e-054106212642343
Pubmed

The Musashi RNA binding proteins direct the translational activation of key pituitary mRNAs.

MSI1 MSI2

5.50e-054106238467682
Pubmed

CD4 raft association and signaling regulate molecular clustering at the immunological synapse site.

TLN2 PRKCQ

5.50e-054106215128768
Pubmed

Multiple congenital malformations of Wolf-Hirschhorn syndrome are recapitulated in Fgfrl1 null mice.

NSD2 FGFR3

5.50e-054106219383940
Pubmed

A CBS haplotype and a polymorphism at the MSR gene are associated with cardiovascular disease in a Spanish case-control study.

CBS MTR

5.50e-054106217553479
Pubmed

Maternal gene polymorphisms involved in folate metabolism as risk factors for Down syndrome offspring in Southern Brazil.

CBS MTR

5.50e-054106221045269
Pubmed

B-vitamin intake, metabolic genes, and colorectal cancer risk (United States).

CBS MTR

5.50e-054106212020105
Pubmed

Methyltetrahydrofolate reductase polymorphism influences onset of Huntington's disease.

CBS MTR

5.50e-054106215354395
Pubmed

Forkhead transcription factor FoxM1 regulates mitotic entry and prevents spindle defects in cerebellar granule neuron precursors.

CCND1 CCNB1

5.50e-054106217893320
Pubmed

Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs.

FGF12 FGFR3

5.50e-054106212815063
Pubmed

E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the circadian heme receptor Rev-erb alpha.

MYCBP2 HUWE1

5.50e-054106220534529
Pubmed

RNA binding protein Musashi-1 directly targets Msi2 and Erh during early testis germ cell development and interacts with IPO5 upon translocation to the nucleus.

MSI1 MSI2

5.50e-054106225782991
Cytoband15q15-q21

MFAP1 TLN2

3.16e-054106215q15-q21
Cytoband8q13

LYN VCPIP1

3.43e-041210628q13
GeneFamilyPleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing

BCR ITSN2 ARHGEF9 FGD5

9.85e-0566664722
GeneFamilyRNA binding motif containing

RBM15 RBMXL3 RBM33 MSI1 MSI2

1.08e-03213665725
CoexpressionMULLIGHAN_MLL_SIGNATURE_1_DN

LAMA5 BCR MYO5C CLIP3 FDFT1 CSAD PYCR1 PRKCQ

5.76e-062381068M18841
ToppCellLPS_IL1RA_TNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

ELAPOR2 DCDC2 SFTPB CECR2 MYO5C MTUS1 CSAD C3 PRKCQ

1.28e-092001069e8db082aa4d0597500e4f16a5c0ea3e62c6c59ae
ToppCellControl-Epithelial_alveolar-AT_2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ELAPOR2 DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

1.44e-08184106851e129b3fcc2df083eda05a3afe3717218b1e52b
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ELAPOR2 DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

1.44e-081841068ab2f06906fc7a9931dfa0864ef506832b07fb93e
ToppCellControl-Epithelial_alveolar-AT_2-Differentiating_AT2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ELAPOR2 DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

1.50e-0818510680d2add28ac1f4fa6de7699be009bf8391badaf4c
ToppCellControl-Epithelial_alveolar-AT_2-AT2_Progenitor|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ELAPOR2 DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

1.50e-0818510688ca1374501eca01d8468130b74d50abfd4329fbe
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

SFTPB SLC26A9 MYO5C MTUS1 FDFT1 CFAP221 DHCR24 C3

1.57e-081861068acfa68a2afb7d2b51c9b469a1965fe5cc5d5e64e
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ELAPOR2 DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

1.57e-081861068e83718fabb057100835d3357df407f283d23fe16
ToppCellCOVID-19-lung-AT2|COVID-19 / Disease (COVID-19 only), tissue and cell type

ELAPOR2 SFTPB SLC26A9 MYO5C MTUS1 CFAP221 DHCR24 C3

1.85e-08190106827a1a86620fe9b5ee930d388b32352206485e6d0
ToppCellControl_saline-Epithelial_alveolar-AT_2-Differentiating_AT2|Control_saline / Treatment groups by lineage, cell group, cell type

ELAPOR2 DCDC2 SFTPB CECR2 MYO5C MTUS1 CSAD C3

2.45e-08197106844a59dfb889577b3160a5b13ada1276771a00241
ToppCellLPS_anti-TNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

ELAPOR2 DCDC2 SFTPB MYO5C MTUS1 CSAD DHCR24 C3

2.45e-0819710681485933986921ff45669d9b7501c8d17050b3e97
ToppCellBronchial-NucSeq-Epithelial-Epi_alveolar-AT2|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

ELAPOR2 SFTPB CECR2 SLC26A9 ABCC9 MYO5C MTUS1 CFAP221

2.55e-081981068f948391296c261c473d339069a6d0f20ccd6f38f
ToppCellLPS_only-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

2.45e-071791067fd2cbee532e7b44113410dca82aec7db1a7fb69f
ToppCellControl-Epithelial_alveolar-AT_2-AT2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

2.75e-071821067e97681a4102f3095d5d9e90ad70f1dc46e90983a
ToppCellLPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 CCND1 MYO5C MTUS1 C3

2.96e-07184106742ce855b4f8475a8298192feec785bdc69bc5bb0
ToppCellCOVID-19-Epithelial_cells-AT2|COVID-19 / group, cell type (main and fine annotations)

SFTPB SLC26A9 MYO5C MTUS1 CFAP221 DHCR24 C3

2.96e-071841067369b82f793deab672204558ae4e112cfa5aa9ccc
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.07e-071851067fefaf227d89f680d6f3e91c4a94e26ab4d0dc6c3
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.07e-071851067929b68b05b7686341329ac756d7df172cb4b810b
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.18e-0718610674e94158db52df41d71e67b02b9895a358eebee0f
ToppCellLPS-antiTNF-Epithelial_alveolar|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.30e-071871067201ff693e4756ee3e44762885b3a303a77eb535b
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ELAPOR2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.30e-07187106758d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCellLPS-IL1RA-Epithelial_alveolar|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.42e-0718810676164d467b612767ceba15de34176bcc8e8c36ab8
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.42e-07188106743a0508d2524a5b310e89e9422843dcaab999bc3
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.42e-0718810674bdf8d49af0e9da349b16e3f012e1b0eec04cc4f
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_1-AT2_Progenitor|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

3.54e-0718910675f883ef4cc0383142d538ae61f4fb40dfdb8ef18
ToppCellCOVID-19-lung-AT2|lung / Disease (COVID-19 only), tissue and cell type

SFTPB SLC26A9 MYO5C MTUS1 CFAP221 DHCR24 C3

3.80e-071911067276455a64c2c3503d5048615762eb2ee37f0ac70
ToppCellhuman_hepatoblastoma-Tumor_cells|World / Sample and Cell Type and Tumor Cluster (all cells)

ASXL1 DCDC2 GPBP1 RBM33 MSI2 SYNJ2 MTR

3.94e-071921067916fbec1c7ab7969bda711886ac88e877e30c280
ToppCellEpithelial-alveolar_epithelial_cell_type_2|World / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB CECR2 SLC26A9 MYO5C MTUS1 CFAP221

3.94e-07192106758c3737be7acce39fd2b91d70d6d7b2bbaa4f710
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_2-D122|Adult / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB CECR2 ABCC9 MYO5C MTUS1 CFAP221

3.94e-07192106706013a07e3a873b1d1c0451643c528593ac32a9c
ToppCellnucseq-Epithelial-Epithelial_Alveolar-AT2-AT2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

ELAPOR2 SFTPB CECR2 SLC26A9 ABCC9 MTUS1 CFAP221

4.08e-071931067fd4d3c0d7caf8a2fff5b3d901fc28d19a8163cdf
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_2|Adult / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB CECR2 SLC26A9 MTUS1 CFAP221 C3

4.08e-071931067738f4f0a9ddde2432b429ab46838e353b1790589
ToppCellhuman_hepatoblastoma|World / Sample and Cell Type and Tumor Cluster (all cells)

ASXL1 DCDC2 GPBP1 RBM33 MSI2 SYNJ2 MTR

4.08e-071931067e6a688bc834f845ff64dae1be64f073eec5091a1
ToppCellnucseq-Epithelial-Epithelial_Alveolar-AT2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

ELAPOR2 SFTPB CECR2 SLC26A9 ABCC9 MTUS1 CFAP221

4.08e-071931067f3cc7cfdbc164a4ed42f87647111522b7d393bcb
ToppCell3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ELAPOR2 SFTPB CECR2 SLC26A9 MTUS1 DHCR24 C3

4.53e-0719610677e5addaa844e66f8160e05858c341866a80aed23
ToppCell(7)_Epithelial-B_(AT2)|World / Lung cell shreds - cell class (v4) and cell subclass (v4)

ELAPOR2 SFTPB SLC26A9 MTUS1 CFAP221 DHCR24 C3

4.53e-071961067345d4cc062b43bca9d506fbf23363469a9ba496f
ToppCellLPS_IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3 PRKCQ

4.85e-071981067285f729140b1df029c24f6ca1d2438470ac51794
ToppCellLPS_anti-TNF-Epithelial_alveolar-AT_1-2_Progenitor|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

DCDC2 SFTPB CCND1 MYO5C MTUS1 DHCR24 C3

4.85e-071981067f006d68e6c51923be7772eea118546a5762e8a5e
ToppCellLPS_only-Epithelial_alveolar|LPS_only / Treatment groups by lineage, cell group, cell type

DCDC2 SFTPB CCND1 MYO5C MTUS1 DHCR24 C3

4.85e-071981067655df75b9692d815c7f6910275e1f684ac63bf62
ToppCell343B-Epithelial_cells|343B / Donor, Lineage, Cell class and subclass (all cells)

ELAPOR2 SFTPB MTUS1 FDFT1 DHCR24 PYCR1 C3

4.85e-0719810670756a5d01572343abce77e7584b816c2c2e9d9c7
ToppCell5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ELAPOR2 SFTPB SLC26A9 ABCC9 MTUS1 DHCR24 C3

5.01e-0719910672dc33804f6691d7c9682e6c9b885e945fb97fc36
ToppCellLPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / Treatment groups by lineage, cell group, cell type

SFTPB CECR2 CCND1 MYO5C MTUS1 CSAD C3

5.19e-0720010672dadf317a42a7e27cc1fac74f91b806c93a57108
ToppCelldroplet-Large_Intestine-COLON_PROXIMAL-30m-Epithelial-Lgr5+_amplifying_undifferentiated_cell|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DCDC2 CCND1 MTUS1 TLN2 ATIC PRRC2B

3.10e-061681066d69452e2cfeb74023b5cf3d09064d7dcad0008ec
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB MYO5C MTUS1 C3 PRKCQ

4.47e-0617910667db6b97a1c4c7a163d5da4351ba36ac1785d9d7b
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB MYO5C MTUS1 C3 PRKCQ

4.62e-061801066b798a3fa2dd15b68aa4267f665559527043dcc07
ToppCellControl-Epithelial_cells-AT2|Control / group, cell type (main and fine annotations)

ELAPOR2 SFTPB CECR2 ABCC9 MTUS1 CFAP221

4.62e-061801066198b19e7910b4a8cc7e820c525ab357c7f99f578
ToppCelldroplet-Marrow-nan-3m-Myeloid-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

TPR MYCBP2 CECR2 F13A1 ITSN2 STAG2

4.92e-061821066f8c73baaaca145e2efc48f10f636feb79c8fc779
ToppCellChildren_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB CECR2 ABCC9 MTUS1 CFAP221

5.08e-0618310666847c1252d6bb105524f812658112517fd351eab
ToppCellLPS_only-Epithelial_alveolar-AT_2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB MYO5C MTUS1 C3 PRKCQ

5.08e-061831066e972432dd4d1bd31bb0982f4df3061e5e152658f
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CECR2 MYO5C MTUS1 C3

5.24e-0618410667cc5796557379c3d1db078c1aeda40659c6e401c
ToppCelldroplet-Marrow-nan-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

TPR MYCBP2 CECR2 F13A1 ITSN2 STAG2

5.41e-0618510667adfa929930cfa795cbfbd9f1a0b439e08aa765d
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

SFTPB CECR2 MYO5C MTUS1 CFAP221 DHCR24

5.57e-0618610662ea5ff14861e5f91d0e6a5767c403a24045d715c
ToppCelldroplet-Thymus-nan-18m-Myeloid-nan|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DCDC2 CCND1 CBS MYO5C C3 FGFR3

5.75e-061871066ed69e7cbd6fb59363b0e26f24887fc49405397ce
ToppCellLPS_only-Epithelial_alveolar-AT_1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DCDC2 SFTPB CCND1 MYO5C MTUS1 C3

5.75e-061871066ff26a533d310126521efe1d05cf8b9d32e524550
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_2-D175|Adult / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB MTUS1 CFAP221 DHCR24 C3

5.93e-061881066ec38def1fdbb34ed9b30244806975bd5a4370164
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_2-D231|Adult / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB CECR2 SLC26A9 MTUS1 C3

6.11e-061891066dab54a52358f66a8a9460cd6089a06c5fa7e7a5d
ToppCellCOVID-19-lung-Secretory|lung / Disease (COVID-19 only), tissue and cell type

SFTPB CYP24A1 MYO5C MSI2 MTUS1 FGFR3

6.11e-06189106684d48e3ed25bebb8bb8074b3a2c5e2e88cff7f25
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ELAPOR2 DCDC2 SFTPB CECR2 MTUS1 FGFR3

6.49e-06191106634cc997e4e5c727495f321e6807a84aa124da486
ToppCellChildren_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2|Children_(3_yrs) / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB CECR2 MYO5C MTUS1 CFAP221

6.49e-061911066a0332a4ef629510fb313ec119195c44a3f704a80
ToppCell(04)_Pre-ciliated|World / shred by cell type and Timepoint

ILDR2 KIAA0586 XK MFAP1 TBC1D31 DNAH8

6.49e-06191106637cf121e6e80760c8519075b7845b9029958a988
ToppCell(7)_Epithelial-E_(AT2)|World / Lung cell shreds - cell class (v4) and cell subclass (v4)

ELAPOR2 SFTPB CCND1 MYO5C DHCR24 C3

6.49e-0619110660fc8d109d5c50957ceef5b8b8b818b0c598b1bbe
ToppCellChildren_(3_yrs)-Epithelial|Children_(3_yrs) / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB CECR2 MYO5C MTUS1 CFAP221

6.49e-061911066e432c6e1ae82dddf84314ce73d2b7a991630d905
ToppCellChildren_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB SLC26A9 MYO5C MTUS1 CFAP221

6.69e-061921066cc9911e182a289779a2612bc213daae5607689e7
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ELAPOR2 SFTPB SLC26A9 MTUS1 CFAP221 LRMDA

6.69e-061921066fb2f0e897228f808d9ff734ad05e9b49dc38fa50
ToppCell5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.0.3|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

6.89e-0619310668646e573f2d2ff175f3d02bfdf214e65f3b614d3
ToppCell3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.4.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

6.89e-061931066043dd0fc2f93e0bd1ca34ac3e196622b3e91df0f
ToppCellfacs-Lung-24m-Mesenchymal-fibroblast-adventitial_fibroblast|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ILDR2 ABCC9 CPZ CLIP3 C3 MMP3

6.89e-061931066e27885a9e1a2a3e165c5366d4cfcda05c5454483
ToppCellfacs-Lung-24m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l1|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ILDR2 ABCC9 CPZ CLIP3 C3 MMP3

7.09e-061941066c9e589fe7df6a9b377654581a2aebb607cbb03b9
ToppCellcellseq-Epithelial-Epithelial_Alveolar-AT2-AT2|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

7.30e-0619510666867f9c56ea27a17c8c4099aae0d79903c3748a5
ToppCellcellseq-Epithelial-Epithelial_Alveolar-AT2|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

7.30e-061951066955a0a7244cd7eaf006a39e1bd03333baf6f30a4
ToppCell356C-Epithelial_cells-Epithelial-A_(AT2)|356C / Donor, Lineage, Cell class and subclass (all cells)

ELAPOR2 SFTPB MTUS1 DHCR24 C3 LRMDA

7.52e-06196106693a5d9b8bcff7d07596ef1f4f2b74f043835fc69
ToppCell356C-Epithelial_cells-Epithelial-A_(AT2)-|356C / Donor, Lineage, Cell class and subclass (all cells)

ELAPOR2 SFTPB MTUS1 DHCR24 C3 LRMDA

7.52e-0619610664715f19f844e7244fc4bc446cba7c8088c600fc3
ToppCell343B-Epithelial_cells-Epithelial-B_(AT2)|343B / Donor, Lineage, Cell class and subclass (all cells)

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

7.74e-061971066f3ca63c7902d7530a29a85eb54f69b303031d150
ToppCellLPS_only-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_only / Treatment groups by lineage, cell group, cell type

DCDC2 SFTPB MYO5C MTUS1 C3 PRKCQ

7.74e-0619710661a1bee8da6e04b65935c40373eaee4d6c046d9a1
ToppCellControl_saline-Epithelial_alveolar-AT_2|Control_saline / Treatment groups by lineage, cell group, cell type

ELAPOR2 DCDC2 SFTPB MYO5C MTUS1 C3

7.74e-061971066b8f62fcd6eb8f47b3cc41f616126f82c68a36e87
ToppCellLPS_anti-TNF-Epithelial_alveolar-AT_2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

DCDC2 SFTPB MTUS1 DHCR24 C3 PRKCQ

7.74e-0619710661638959d7aecb9fc5285eb7e4a3103ca437989e2
ToppCell343B-Epithelial_cells-Epithelial-B_(AT2)-|343B / Donor, Lineage, Cell class and subclass (all cells)

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

7.74e-061971066f98720cab066579fdac3ba24fb6fe4c5759dae4e
ToppCellLPS_anti-TNF-Epithelial_alveolar-AT_1-2_Progenitor-Progenitor_AT1-AT2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

ELAPOR2 SFTPB CCND1 MTUS1 DHCR24 C3

7.97e-06198106650852713c017217c79777c95857097103bcf2fbe
ToppCellLPS_only-Epithelial_alveolar-AT_2|LPS_only / Treatment groups by lineage, cell group, cell type

DCDC2 SFTPB MTUS1 DHCR24 C3 PRKCQ

7.97e-061981066d087e738d69ca9853553fde46d4e7a8906439d32
ToppCellFetal_29-31_weeks-Epithelial-club_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

SFTPB MSI2 MTUS1 FDFT1 DHCR24 FGFR3

7.97e-0619810665fc25b008a4d8d6bec83923a16f64dd9e1ff1f2d
ToppCellParenchymal-NucSeq-Epithelial-Epi_alveolar-AT2|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

ELAPOR2 SFTPB CECR2 SLC26A9 MTUS1 CFAP221

7.97e-0619810662e2a4e1756bba6f4fbe529559a97d2993c890b4b
ToppCellLPS_anti-TNF-Epithelial_alveolar|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

DCDC2 SFTPB MYO5C MTUS1 DHCR24 C3

7.97e-06198106653e9ed1b19cb26be58da0f37057caca0cdfaabeb
ToppCellLPS_IL1RA_TNF-Epithelial_alveolar-AT_2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

ELAPOR2 DCDC2 SFTPB MTUS1 C3 PRKCQ

7.97e-061981066aa80315395cb5dffc25927c8a77cd2037aea8772
ToppCellwk_15-18-Epithelial-Airway_epithelial_progenitor|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

DCDC2 SFTPB PPP1R3B LAMA5 MYO5C FGFR3

7.97e-061981066c477405b093f4e5374e57bcacf1fb204a0f7eb3b
ToppCellBronchial-NucSeq-Epithelial-Epi_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

ELAPOR2 SFTPB CECR2 MYO5C MTUS1 CFAP221

8.20e-061991066725610310e5c5fd7120c0be9acb55bf152026ddd
ToppCellSkin|World / Skin and Kidney Cells in Lupus Nephritis Patients.

MYCBP2 CDHR1 CCND1 SLC38A2 DHCR24 FGFR3

8.20e-0619910666be1340413ee868c610b6e3f58c65b493eb22bb5
ToppCellParenchymal-NucSeq-Epithelial-Epi_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

ELAPOR2 SFTPB CECR2 MYO5C MTUS1 CFAP221

8.20e-0619910668587bd98de7767a575088afbea07a1feb4516b9b
ToppCellBiopsy_Other_PF-Epithelial-AT2|Biopsy_Other_PF / Sample group, Lineage and Cell type

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

8.20e-0619910669a65acfe9bf500db72142469cf17bf0973540001
ToppCell343B-Epithelial_cells-Epithelial-B_(AT2)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)

AHCYL1 SFTPB SLC26A9 MTUS1 DHCR24 C3

8.20e-061991066df157604a7e2b6e7fa2d21660ca749a3552b945c
ToppCellwk_15-18-Epithelial-Proximal_epithelial-Late_airway_progenitor|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

SFTPB LAMA5 MYO5C DHCR24 DLX3 FGFR3

8.20e-061991066494461665f945ce6c97299c58f7785e90dec5812
ToppCellBiopsy_Control_(H.)-Epithelial-AT2|Biopsy_Control_(H.) / Sample group, Lineage and Cell type

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

8.20e-0619910665323d49d3be980605b3e609b7f03bddba6e50e8a
ToppCell343B-Epithelial_cells-Epithelial-B_(AT2)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)

AHCYL1 SFTPB SLC26A9 MTUS1 DHCR24 C3

8.20e-06199106648626e54ce94b5ea3001fc5d447509a50c073aa4
ToppCellBiopsy_IPF-Epithelial-AT2|Biopsy_IPF / Sample group, Lineage and Cell type

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

8.20e-061991066c841d475703d3489161fb7904526bd7563d5fb0f
ToppCellTransplant_Alveoli_and_parenchyma-Epithelial-Type_2_alveolar|Transplant_Alveoli_and_parenchyma / Tissue, Lineage and Cell class of Lung Cells from 10X

ELAPOR2 SFTPB CCND1 MTUS1 DHCR24 C3

8.20e-061991066e28ace2ca680c6154398e17110aa1838dd7a5548
ToppCellBrain_organoid-organoid_Tanaka_cellReport-6m-Mesenchymal-BMP_responsible_cell|6m / Sample Type, Dataset, Time_group, and Cell type.

DCDC2 CCND1 MYO5C MSI2 KIF9 MAP3K19

8.44e-0620010665fb90118d3abc28d72bc483e68317255090a04c7
ToppCellSkin-Keratinocytes|Skin / Skin and Kidney Cells in Lupus Nephritis Patients.

CDHR1 CCND1 HUWE1 DHCR24 FGFR3 XRCC6

8.44e-06200106659d72395199bc30df0e811fbc99149694e208860
ToppCellBiopsy_Control_(H.)-Epithelial|Biopsy_Control_(H.) / Sample group, Lineage and Cell type

SFTPB MYO5C MTUS1 CFAP221 DHCR24 C3

8.44e-0620010660afd93c4fdcc118bcfa77f3b59f6ff7d9293a7a4
ToppCellBronchial-10x5prime-Epithelial-Epi_alveolar-AT2|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

ELAPOR2 SFTPB SLC26A9 MTUS1 DHCR24 C3

8.44e-062001066b535323e18d9fb0dde1e0026df142c831e48c29f
ToppCellLPS_only-Epithelial_alveolar-AT_1|LPS_only / Treatment groups by lineage, cell group, cell type

DCDC2 SFTPB CCND1 MYO5C MTUS1 C3

8.44e-0620010669a6ae40f3e17cd44ee5fd73260713b920aa2ea15
ToppCellLPS_only-Epithelial_alveolar-AT_2-Differentiating_AT1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SFTPB MYO5C MTUS1 ACSM5 C3

1.34e-0512710655b0adbcafad31a6759c9bdce2f7f9591a8edc450
ToppCellrenal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

DCDC2 CECR2 MSI2 KLHL3 MMP3

2.29e-0514210655b6b0c611c83b23ef7289854a515b78f6cf84500
ToppCelllung-Type_II_Pneumocytes|lung / shred on tissue and cell subclass

IL13RA1 SFTPB MTUS1 DHCR24 C3

2.70e-0514710658a3039de45b8087f8319e2e37329acf7278219b7
DrugEtomidate [33125-97-2]; Up 200; 16.4uM; HL60; HT_HG-U133A

SFTPB BCR MTUS1 SYNJ2 TLN2 FGFR3 MMP3 PDLIM2

3.32e-0619610482958_UP
Drug6 Pl

SFTPB CCND1 CCNB1 MTR

7.73e-06281044CID000449006
Drugphosphogypsum

CBS FDFT1 CSAD STAG2

7.73e-06281044CID000024928
Drug2-Amino-4-

AHCYL1 CBS MTR

1.49e-05111043CID006326973
Drugponatinib

BCR CSK FGFR3 LYN EPHA3

1.50e-05681045ctd:C545373
DiseaseMalnutrition

CBS MTR

3.54e-0531022C0162429
DiseaseGrowth delay

NSD2 STAG2

3.54e-0531022C0456070
Diseasevon Hippel-Lindau disease (is_implicated_in)

CCND1 MMP3

3.54e-0531022DOID:14175 (is_implicated_in)
Diseasehyperhomocysteinemia (is_implicated_in)

CBS MTR

3.54e-0531022DOID:9279 (is_implicated_in)
Diseasevitamin B12 deficiency (biomarker_via_orthology)

CBS MTR

7.07e-0541022DOID:0050731 (biomarker_via_orthology)
DiseaseParkinsonism (biomarker_via_orthology)

ABCC9 MMP3 LYN

2.22e-04341023DOID:0080855 (biomarker_via_orthology)
DiseaseHematological Disease

XK MTR

3.27e-0481022C0018939
Diseaselung cancer (is_marker_for)

SFTPB CYP24A1 MMP3

3.35e-04391023DOID:1324 (is_marker_for)
DiseaseCarcinoma, Transitional Cell

CCND1 FGFR3 STAG2

3.89e-04411023C0007138
DiseaseMammary Carcinoma, Human

NSD2 CYP24A1 CCND1 SYNJ2 ITSN2 MTR FGD5 MMP3

4.84e-045251028C4704874
DiseaseMammary Neoplasms, Human

NSD2 CYP24A1 CCND1 SYNJ2 ITSN2 MTR FGD5 MMP3

4.84e-045251028C1257931
DiseaseMammary Neoplasms

NSD2 CYP24A1 CCND1 SYNJ2 ITSN2 MTR FGD5 MMP3

4.96e-045271028C1458155
DiseaseBreast Carcinoma

NSD2 CYP24A1 CCND1 SYNJ2 ITSN2 MTR FGD5 MMP3

5.68e-045381028C0678222
Diseaserhinitis (biomarker_via_orthology)

MFN1 C3

9.00e-04131022DOID:4483 (biomarker_via_orthology)
DiseaseDown syndrome (implicated_via_orthology)

CBS SYNJ2

1.21e-03151022DOID:14250 (implicated_via_orthology)
DiseaseNeoplasm of uncertain or unknown behavior of bladder

FGFR3 STAG2

1.21e-03151022C0496930
DiseaseBenign neoplasm of bladder

FGFR3 STAG2

1.21e-03151022C0154017
DiseaseCarcinoma in situ of bladder

FGFR3 STAG2

1.21e-03151022C0154091
DiseaseMalignant neoplasm of breast

NSD2 CYP24A1 CCND1 MSI1 GGA3 EPG5 SYNJ2 ITSN2 MTR FGD5 MMP3

1.23e-03107410211C0006142
Diseaselung non-small cell carcinoma (is_implicated_in)

SFTPB NSD2 CYP24A1 CCND1

1.40e-031391024DOID:3908 (is_implicated_in)
DiseaseAntibody Deficiency Syndrome

EPG5 C3

1.56e-03171022C0003257
Diseaseemphysema imaging measurement

MYCBP2 NSD2 MSI2 MMP3

1.68e-031461024EFO_0007626
DiseaseCarcinoma of bladder

FGFR3 STAG2

1.75e-03181022C0699885
Diseaseseborrheic dermatitis

ELAPOR2 C1orf94

2.16e-03201022EFO_1000764
Diseasegastric ulcer (biomarker_via_orthology)

F13A1 MMP3

2.38e-03211022DOID:10808 (biomarker_via_orthology)
DiseaseDisproportionate short stature

EVC2 DHCR24 FGFR3

2.44e-03771023C0878659
Diseaseleptin measurement

CSAD DNAH8 C1orf94

2.81e-03811023EFO_0005000
DiseaseImmunologic Deficiency Syndromes

EPG5 C3

2.86e-03231022C0021051
DiseaseLymphoma, T-Cell, Cutaneous

PRKCQ FGFR3

2.86e-03231022C0079773
DiseaseDrug toxicity

MTR C3 ATIC

3.12e-03841023C0013221
DiseaseAdverse reaction to drug

MTR C3 ATIC

3.12e-03841023C0041755

Protein segments in the cluster

PeptideGeneStartEntry
MAEAVKPQRRAKAKA

EPG5

1

Q9HCE0
QKKTMVLGTPVKIEA

CDHR1

581

Q96JP9
VQKLEKMTVGKKPVN

ANKRD30B

51

Q9BXX2
QRQPTKKMSKVKGLV

COPS7B

246

Q9H9Q2
KRMPSRKQTGVFGVK

BCR

1041

P11274
TVVAPGKEKALMKAV

CTSV

226

O60911
RKSLKVVPEGIRMNK

C3

926

P01024
VVICANPKGMKIKSG

ACSM5

376

Q6NUN0
RLIKPKVMEGTVAAQ

CSK

166

P41240
KAIGKLPIAMRAVTN

ABCC9

246

O60706
KCVQKEVLPSMRKIV

CCND1

46

P24385
KRTGLVVVKNMKIVG

CDADC1

86

Q9BWV3
VKMAKIPVSLGRRNK

AHDC1

476

Q5TGY3
GDKLLKQKVAMPVIS

C1orf94

181

Q6P1W5
EAEVRMVNGKPKKVR

DLX3

116

O60479
MIAQKGKRPQRTKAE

CECR2

286

Q9BXF3
QKKKTGVMLPRVVLT

ASXL1

161

Q8IXJ9
AMTVRKVPKQKGVNS

ARHGEF9

446

O43307
KLAMSGKIIIRNPIK

RBM15

431

Q96T37
IKSIQGIHPAKKAIM

RBM33

1051

Q96EV2
AQPKMVTRTKKIFVG

MSI2

101

Q96DH6
GSKRKMSLNPIAKQI

ARHGAP36

221

Q6ZRI8
LRVRKKTGGEKMPVQ

ITSN2

1271

Q9NZM3
RKMGVKLTPHNKETV

PYCR1

46

P32322
KEVLSARKQKAQGMP

MFN1

286

Q8IWA4
PKAQKGTKVRMSVQR

MSGN1

111

A6NI15
RIKKQVSPTEMVAKF

BEND3

226

Q5T5X7
VATKNVAPMKAPKRM

CYREN

21

Q9BWK5
MSQAGAQEAPIKKKR

MUSTN1

1

Q8IVN3
IVSAVMKVPSAQGKL

OR1F12P

221

Q8NHA8
KGRVMQIIVKGKNVD

PRKCQ

66

Q04759
KTILPKVMQVKNFGR

MFAP1

371

P55081
ALVRGVFMKVVKPKA

LRMDA

131

Q9H2I8
PVEKKAVGAVMRKRK

MAJIN

51

Q3KP22
MVPESRTGRSQKVKK

INKA2

236

Q9NTI7
KAKVMSRAVLQPKDA

MTUS1

511

Q9ULD2
KSRAPRMLVIKKGNT

GPBP1

166

Q86WP2
DSGPVVKKIREMQKF

MMP3

56

P08254
RKQGMEQKISKFSPI

BSN

3361

Q9UPA5
KGAVKIRKGQAVTLM

FDFT1

311

P37268
KPRMQIILRGQKVKT

MORC3

261

Q14149
GAQKARSIKMIERPK

NEK5

336

Q6P3R8
TPKMKKVESVLRQGL

DNAH8

666

Q96JB1
KEGTLMKVTGKNRRP

FGD5

1116

Q6ZNL6
VKCIKMKQAPEILGS

NSD2

16

O96028
RIMKNAIPQTGKIAK

NFYB

66

P25208
SPQVERKMSAVFKKQ

EVC2

421

Q86UK5
PIKVSRVGSAMVNAK

F13A1

256

P00488
SIVLQAAVPKSMKVK

GGA3

641

Q9NZ52
MGTRKKVHAFVRVKP

KIF9

1

Q9HAQ2
ARGAASKVKVPMKFN

LAMA5

2726

O15230
SKVKVPMKFNGRSGV

LAMA5

2731

O15230
SKITPAMAARIKQIK

HUWE1

1036

Q7Z6Z7
QPKMVTRTKKIFVGG

MSI1

101

O43347
KGKKNSVPVTVAMVE

NOC2L

141

Q9Y3T9
MGSKAVKPVLVKNIT

ELAPOR2

266

A8MWY0
SVQIMVKDNAGKIKP

IL13RA1

201

P78552
NKKRGIFPKVATNIM

MEIS3P2

246

A8K0S8
VMNRAKKAGKSVGVV

ALPG

151

P10696
KAKINMAGAKRVPTA

CCNB1

16

P14635
GPQKLVRIVSMDKAK

CARD14

766

Q9BXL6
VIKKVIIPARMKRAG

CPZ

561

Q66K79
QRVRSAFQKKLMKPG

CYP24A1

156

Q07973
MRKNVPKVLVVVTDG

COL12A1

2421

Q99715
KPKGRQAKMAFVNSV

ELOA

681

Q14241
TKKQIVRVEPLVTMG

DHCR24

126

Q15392
LKKIGDTPMVRINKI

CBS

81

P35520
MKKVGVTVVGPQKKI

EPHA3

951

P29320
KVAPVLKERMVKEGS

CSAD

436

Q9Y600
KVAVKTLKPGTMSVQ

LYN

271

P07948
KVMIVVGGQAPKAIR

KLHL3

301

Q9UH77
KDRAAKPVTVAVKML

FGFR3

496

P22607
VGAKKVHQVTMTQPK

CLIP3

496

Q96DZ5
VAKRIPGKQAVVVMA

RNF41

276

Q9H4P4
KKRPMEVVNTEVKPV

DCDC2

106

Q9UHG0
PKEMGRETTKVKIQR

MAP3K19

1011

Q56UN5
ASGMVAPAVQEKKVK

PPP1R3B

46

Q86XI6
VKAALKRTIQKTVPM

OR10C1

296

Q96KK4
MAVVKTPSRGLKNAK

CFAP221

1

Q4G0U5
GQIMKGNRVKKTKPS

FGF12

181

P61328
VVTPKGVKLNKNVMT

RTL1

781

A6NKG5
LKMKVTSGRVQQPAK

TBC1D31

366

Q96DN5
KRIQAMIPKGALAVA

SFTPB

216

P07988
VDGMKVKGRAVKIRP

SYNJ2

951

O15056
FRQKVIAKTGMDPQK

SLC26A9

546

Q7LBE3
MATVTKAPKKQIQFA

AHCYL1

31

O43865
PQVIKSARVMKKAVG

MTR

731

Q99707
VEVKAVPVSQKKMSL

MYCBP2

2306

O75592
QEVKQTPVIMAKIKG

ODF3L1

26

Q8IXM7
TFLKKTRAGGVMKIV

DIS3

6

Q9Y2L1
EKMLKPTGRVVGIIK

DIS3

336

Q9Y2L1
PIMVTKVAERGKAKD

PDLIM2

26

Q96JY6
PEQVGKMKAIVEKLR

XRCC6

456

P12956
GKAIMVAQTIKPAFK

RBMXL3

76

Q8N7X1
KPSTGKRKVVEGMQL

STAG2

1076

Q8N3U4
TAAAVAKIVKPGMKL

TPR

381

P12270
AMVEGLQVTVPDKKK

ILDR2

16

Q71H61
LVKKEPMKSVQKIGA

SLC38A2

461

Q96QD8
EGKKMAVTRTRTKPV

THG1L

261

Q9NWX6
MKRTGAIKPRAVKVE

PRRC2B

2211

Q5JSZ5
PQVLSMKFKTGVKRA

ATIC

471

P31939
VTGAPKKNTELVKVM

VCPIP1

106

Q96JH7
KQRPQKIRMLDGSVK

TLN2

86

Q9Y4G6
MIKQFKGVPGVKAER

TYW1

456

Q9NV66
MEQPVTKKVKIQGRG

WDR87

1211

Q6ZQQ6
MADPRVRQIKIKTGV

TBCA

1

O75347
VSITKKRQMPKNGLS

XK

101

P51811
RTVLKQKAQSMPVFK

KIAA0586

116

Q9BVV6
GSMITVKSAKQVIKP

MYO5C

601

Q9NQX4